Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Brii Biosciences
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
- Large Molecule
- Other Names / Subsidiaries
- Brii Biosciences Limited